Atlantic Healthcare to present a poster at the Crohn’s & Colitis Foundation IBD: Innovate conference in New York on Tuesday, November 13, 2018


Cambridge, UK; November 12, 2018. Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist pharmaceutical company focused on developing and commercializing gastrointestinal therapeutics, will present a poster at the inaugural…

Read More

Atlantic Healthcare reports results from Phase 1 trial of tablet for Crohn’s


Oral alicaforsen appears safe and well-toleratedCambridge, UK; 27 September 2018. Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist pharmaceutical company focused on developing and commercializing gastrointestinal…

Read More

Atlantic Healthcare secures acceptance of brand name Camligo™ for alicaforsen enema to treat pouchitis


Cambridge, UK; September 13, 2018. Atlantic Healthcare plc (“Atlantic Healthcare” or “Company”), a specialist pharmaceutical company focused on developing and commercializing gastrointestinal therapeutics, has secured acceptance of Camligo™ as the…

Read More

Strategic appointment expands Atlantic Healthcare executive team


U.S. President and COO appointed to lead commercialisation of alicaforsenCambridge, UK; August 2, 2018. Atlantic Healthcare plc (Atlantic Healthcare), a specialist gastrointestinal (GI) pharmaceutical company, developing treatments for inflammatory…

Read More

St Mark’s Pouch Masterclass: Study day celebrates 40th anniversary of first pouch surgery at the hospital


On 29 June 2018, clinicians from St Mark’s Hospital in London will host The St Mark’s Pouch Masterclass, celebrating the 40th anniversary year of the first IPAA surgery at the hospital.Back in 1978 Sir Alan Parks at St. Mark’s Hospital published the…

Read More

Atlantic Healthcare completes patient enrollment to its Phase 3 study of alicaforsen to treat IBD Pouchitis


Study completion and top-line data expected in H1 2019Cambridge, UK; May 02, 2018. Atlantic Healthcare plc (Atlantic Healthcare), an emerging trans-Atlantic pharmaceutical company with a core focus on gastrointestinal (GI) disorders, today announced…

Read More